PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 85 filers reported holding PHATHOM PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $18,853 | -4.1% | 1,818 | +32.4% | 0.00% | 0.0% |
| Q2 2023 | $19,661 | +100.6% | 1,373 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $9,803 | -37.7% | 1,373 | -2.1% | 0.00% | 0.0% |
| Q4 2022 | $15,730 | +1.3% | 1,402 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $15,534 | +31.3% | 1,402 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $11,833 | -38.0% | 1,402 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $19,081 | -83.7% | 1,402 | -76.4% | 0.00% | -50.0% |
| Q4 2021 | $116,879 | -38.7% | 5,942 | 0.0% | 0.00% | -33.3% |
| Q3 2021 | $190,738 | -5.2% | 5,942 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $201,137 | +49.3% | 5,942 | +65.7% | 0.00% | +50.0% |
| Q1 2021 | $134,728 | +13.1% | 3,587 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $119,160 | -9.4% | 3,587 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $131,535 | +11.4% | 3,587 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $118,048 | +27.5% | 3,587 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $92,616 | – | 3,587 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 4,901,358 | $41,368,000 | 8.59% |
| Frazier Life Sciences Management, L.P. | 5,827,415 | $49,183,000 | 4.64% |
| Abingworth LLP | 1,435,106 | $12,112,000 | 3.88% |
| Penn Mutual Asset Management | 86,940 | $734,000 | 0.99% |
| 683 Capital Management, LLC | 1,440,000 | $12,153,000 | 0.86% |
| Western Standard LLC | 109,055 | $920,000 | 0.70% |
| MPM BioImpact LLC | 193,326 | $1,632,000 | 0.45% |
| Newtyn Management, LLC | 255,767 | $2,159,000 | 0.41% |
| StepStone Group LP | 422,085 | $3,562,000 | 0.38% |
| Avidity Partners Management LP | 1,919,800 | $16,203,000 | 0.37% |